Premium
Th17 vs. Th1 cytokine production against candida and responses to zymosan in patients with chronic airway and gut mucosal inflammation
Author(s) -
Jyonouchi Harumi,
Geng Lee,
Aguila Helen A,
CushingRuby Agnes,
Monteiro Iona
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.899.9
Subject(s) - medicine , immunology , cytokine , peripheral blood mononuclear cell , inflammation , zymosan , candida albicans , biology , microbiology and biotechnology , biochemistry , in vitro
Th17 cells appear important for defense against fungal pathogens but they can also aggravate mucosal inflammation as observed in inflammatory bowel diseases (IBD). We evaluated Th17 vs. Th1 cytokine production against candida albicans in children with airway and gut mucosal inflammation along with their responses to zymosan, a fungal derived TLR2/6 agonist. The study included children with recurrent otitis media/chronic rhinosinusitis (ROM/CRS; N=26, 17/28 diagnosed with asthma, median 6.2 y), IBD (N=18, median 13.8 y), food allergy (FA, N=41, median 3.6 y), and normal controls (N=21, median 7 y). Peripheral blood mononuclear cells (PBMCs) were tested for cytokine production with candida Ag or with zymosa. ROM/CRS and IBD but not FA PBMCs revealed higher IL‐17 production while FA and ROM/CRS but not IBD PBMCs revealed higher IFN‐γ production than controls (p<0.05). IL‐17 and IFN‐γ levels were positively correlated in FA/control cells but not in ROM/CRS/IBD cells due to higher IL‐17 production by ROM/CRS/IBD cells. With zymosan, FA PBMCs produced less IL‐10 than controls (p<0.05) and also revealed less IL‐1β production than ROM/CRS/IBD cells (p<0.01). Our results indicate aberrant Th17 vs. Th1 responses in ROM/CRS and IBD patients while FA patients may have aberrant TLR2/6 responses. Funded by Jonty Foundation/ARI.